CD28H expression identifies resident memory CD8 + T cells with less cytotoxicity in human peripheral tissues and cancers. (1st February 2019)

• Record Type: Journal Article
• Authors: Tian, Yu; Sun, Yi; Gao, Fan; Koenig, Michelle R.; Sunderland, Alexander; Fujiwara, Yuki; Torphy, Robert J.; Chen, Lieping; Edil, Barish H.; Schulick, Richard D.; Zhu, Yuwen
• Is Part Of: Oncoimmunology. Volume 8:Number 2(2019)
• Publication Date: 2019-02-01
• Subjects: Tissue-resident T cell -- tumor-infiltrating lymphocyte -- B7/CD28 family -- CD28H -- B7-H5; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2018.1538440
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: The CD28H/B7-H5 pathway is a newly identified pathway of the B7 family. In human peripheral blood, the receptor CD28H is preferentially expressed on naïve T cells and repetitive stimulation of T cells leads to the loss of CD28H expression. Here we examined the expression of the CD28H/B7-H5 pathway in human peripheral tissues, as well as in human cancers. We found that CD28H is preferentially expressed on T cells with tissue-resident phenotypes (TRM ). Supporting that, stimulation via IL-15 and TGF-β, presumably major cytokines essential for TRM cell homeostasis, sustains CD28H expression on T cells. The ligand B7-H5 is constitutively expressed on normal epithelium of human oral-gastrointestinal tracts. In human cancers, CD28H is preferentially present on tumor infiltrating lymphocytes (TILs) with TRM features and identifies a TRM subset with less cytotoxicity. Taken together, our studies suggest that the CD28H/B7-H5 pathway involves the interactions between TRM cells and epithelium, and could be important for human TRM homeostasis and function.